Managing Concurrent Medications

  • Denise SharonEmail author


Managing concurrent medications is a balancing act and in the case of RLS, with very limited evidence-based guidelines. It compels the physician to consider the most appropriate treatment for each of the disorders with its own symptomatology, as well as the possible interactions with other conditions, medications, age and person specific parameters. RLS is a lifetime condition, implying the need to adapt concurrent medications to the current patient condition. It is also a disorder with a natural progression that can compound the effects of some concurrent medications. It is therefore, important to regularly review medications’ lists, to devise individual treatment plans and to alert the patients and the other providers to possible interactions.


Restless legs syndrome medications Medications for restless legs syndrome Willis Ekbom disease medications Medication management in Willis Ekbom disease Antihistamine use in restless legs syndrome Antidepressant use and restless legs syndrome 


  1. 1.
    Silber MH, Ehrenberg BL, Allen RP, Buchfuhrer MJ, Earley CJ, Hening WA, Rye DB, Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome. Mayo Clin Proc. 2004;79(7):916–22.PubMedCrossRefGoogle Scholar
  2. 2.
    Bliwise DL, Zhang RH, Kutner NG. Medications aasociated with restless legs syndrome: a case-control study in the US renal data system (USRDS). Sleep Med. 2014;15(10):1241–5.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Sawai Y, Ito K, Itoh M. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol. 1995;116(1):1649–55.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with “non-sedating” antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000;320(7243):1184–7.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Allen RP, Lesage S, Earley CJ. Anti-histamines and benzodiazepines exacerbate daytime restless legs syndrome symptoms [abstract]. Sleep. 2005;28:A279.Google Scholar
  6. 6.
    O’Sullivan RL, Greenberg DB. H2 antagonists, restless leg syndrome, and movement disorders. Psychosomatics. 1993;34(6):530–2.Google Scholar
  7. 7.
    Hogl B, Gschliesser V. Management of restless legs syndrome in the hospital and during surgery. In: Hening WA, Allen RP, Chokroverty S, Earley CJ, Saunders, editors Restless Legs Syndrome. 2009.Google Scholar
  8. 8.
    Högl B, Frauscher B, Seppi K, Ulmer H, Poewe W. Transient restless legs syndrome after spinal anesthesia: a prospective study. Neurology. 2002;59(11):1705–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Karroum EG, Raux M, Riou B, Arnulf I. Acute exacerbation of restless legs syndrome during perioperative procedures: case reports and suggested management. Ann Fr Anesth Reanim. 2010;29(12):920–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Shin YK. Restless leg syndrome: unusual cause of agitation under anesthesia. South Med J. 1987;80(2):278–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Watanabe S, Sakai K, Ono Y, Seino H, Naito H. Alternating periodic limb movement induced by spinal anesthesia in an elderly male. Anesth Analg. 1987;66(10):1031–2.PubMedCrossRefGoogle Scholar
  12. 12.
    Watanabe S, Ono A, Naito H. Periodic leg movements during either epidural or spinal anesthesia in an elderly man without sleep-related (nocturnal) myoclonus. Sleep. 1990;13(3):262–6.PubMedGoogle Scholar
  13. 13.
    Ostojic P, Jovic T, Stojic B. Restless legs syndrome in patients with systemic sclerosis: prevalence and possible causes. Z Rheumatol. 2013;72(6):590–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Winkelmann J, Schadrack J, Wetter TC, Zieglgänsberger W, Trenkwalder C. Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Med. 2001;2(1):57–61.PubMedCrossRefGoogle Scholar
  15. 15.
    Tribl GG, Sycha T, Kotzailias N, Zeitlhofer J, Auff E. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry. 2005;76(2):181–5.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Drotts DL, Vinson DR. Prochlorperazine induces akathisia in emergency patients. Ann Emerg Med. 1999;34(4):469–75.PubMedCrossRefGoogle Scholar
  17. 17.
    Winkelmann J, Wetter T, Stiasny K, Oertel W, Trenkwalder C. Treatment of restless legs syndrome with pergolide-an open clinical trial. Mov Disord. 1998;13(3):586–9.CrossRefGoogle Scholar
  18. 18.
    Romenets S, Dauvilliers Y, Cochen De Cock V, Carlander B, Bayard S, Galatas C, Wolfson C. Restless legs syndrome outside the blood brain barrier; evidence from domperidone. Mov Disord Suppl. 2012;(27).Google Scholar
  19. 19.
    Chang CC, Shiah IS, Chang HA, Mao WC. Does domperidone potentiate mirtazapine-associated restless legs syndrome? Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(2):316–8 (Epub 2005 Nov 23).PubMedCrossRefGoogle Scholar
  20. 20.
    Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry. 1999;60(4):241–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Shin YK, Hong SC, Ihn YK, Jeong JH, Han JH, Lee SP. A case of a patient with both chorea and restless legs syndrome. J Korean Med Sci. 2008;23(3):533–6.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Waldinger MD, Schweitzer DH. Persistent genital arousal disorder in 18 Dutch women: part II. A syndrome clustered with restless legs and overactive bladder. J Sex Med. 2009;6(2):482–97. doi: 10.1111/j.1743-6109.2008.01114.x (Epub 2008 Dec 2).PubMedCrossRefGoogle Scholar
  23. 23.
    Park YM, Park HK, Kim L, Lee HJ, Kang SG. Acute-withdrawal restless legs syndrome following abrupt cessation of short-term tramadol. Psychiatry Investig. 2014;11(2):204–6.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Freye E, Levy J. Acute abstinence syndrome following abrupt cessation of long-term use of tramadol (Ultram): a case study. Eur J Pain. 2000;4(3):307–11.PubMedCrossRefGoogle Scholar
  25. 25.
    Earley CJ, Allen RP. Restless legs syndrome augmentation associated with tramadol. Sleep Med. 2006;7(7):592–3 (Epub 2006 Aug 22).PubMedCrossRefGoogle Scholar
  26. 26.
    Vetrugno R, La Morgia C, D’Angelo R, Loi D, Provini F, Plazzi G, Montagna P. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord. 2007;22(3):424–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Kim SW, Shin IS, Kim JM, Park KH, Youn T, Yoon JS. Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Hum Psychopharmacol 2008;23(7):615–20.Google Scholar
  28. 28.
    Leutgeb U, Martus P. Regular intake of non-opioid analgesics is associated with an increased risk of restless legs syndrome in patients maintained on antidepressants. Eur J Med Res. 2002;7(8):368–78.PubMedGoogle Scholar
  29. 29.
    Berger K. Non-opioid analgesics and the risk of restless leg syndrome-a spurious association? Sleep Med. 2003;4(4):351–2.PubMedCrossRefGoogle Scholar
  30. 30.
    Chen JT, Garcia PA, Alldredge BK. Zonisamide-induced restless legs syndrome. Neurology. 2003;60(1):147.PubMedCrossRefGoogle Scholar
  31. 31.
    Drake ME. Restless legs with antiepileptic drug therapy. Clin Neurol Neurosurg. 1988;90(2):151–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Abril B, Carlander B, Touchon J, Dauvilliers Y. Restless legs syndrome in narcolepsy: a side effect of sodium oxybate? Sleep Med. 2007;8(2):181–3 (Epub 2007 Feb 1).PubMedCrossRefGoogle Scholar
  33. 33.
    Howell MJ, Schenck CH. Restless nocturnal eating: a common feature of Willis-Ekbom syndrome (RLS). J Clin Sleep Med. 2012;8(4):413–9.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Yun CH, Ji KH. Zolpidem-induced sleep-related eating disorder. J Neurol Sci. 2010;288(1–2):200–1.PubMedCrossRefGoogle Scholar
  35. 35.
    Becker PM, Sharon D. Mood disorders in restless legs syndrome (Willis-Ekbom disease). J Clin Psychiatry. 2014;75(7):e679–94.PubMedCrossRefGoogle Scholar
  36. 36.
    Rottach KG, Schaner BM, Kirch MH, Zivotofsky AZ, Teufel LM, Gallwitz T, Messer T. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008;43(1):70–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Brown LK, Dedrick DL, Doggett JW, Guido PS. Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. Sleep Med. 2005;6(5):443–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Baughman KR, Bouguet CC, Ober SK. Gender differences in the association between antidepressant use and restless legs syndrome. Mov Disord. 2009;24(7):1054–9.Google Scholar
  39. 39.
    Goerke M, Rodenbeck A, Cohrs S, Kunz D. The influence of the tricyclic antidepressant amitriptyline on periodic limb movements during sleep. Pharmaco-psychiatry. 2013;46(3):108–13. doi: 10.1055/s-0032-1331702 (Epub 2013 Jan 4).CrossRefGoogle Scholar
  40. 40.
    Evidente VG, Caviness JN. Focal cortical transient preceding myoclonus during lithium and tricyclic antidepressant therapy. Neurology. 1999;52(1):211–3.PubMedCrossRefGoogle Scholar
  41. 41.
    Husain MRG, Novak M, Jindal R, Shapiro CM. Periodic leg movements in patients on different antidepressant therapies. Sleep Res. 1997;26.Google Scholar
  42. 42.
    Garvey MJ, Tollefson GD. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry. 1987;44(3):269–72.PubMedCrossRefGoogle Scholar
  43. 43.
    Patterson JF. Myoclonus caused by a tricyclic antidepressant. South Med J. 1990;83(4):463–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Black KJ, Kilzieh N. Severe imipramine-induced myoclonus in a patient with psychotic bipolar depression, catatonia, and schizencephaly. Ann Clin Psychiatry. 1994;6(1):45–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Massand P. Desipramine-induced oral-pharyngeal disturbances: stuttering and jaw myoclonus. J Clin Psychopharmacol. 1992;12(6):444–5.CrossRefGoogle Scholar
  46. 46.
    Guilleminault C, Raynal D, Takahashi S, Carskadon M, Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand. 1976;54(1):71–87.PubMedCrossRefGoogle Scholar
  47. 47.
    Casas M, Garcia-Ribera C, Alvarez E, Udina C, Queralto JM, Grau JM. Myoclonic movements as a side-effect of treatment with therapeutic doses of clomipramine. Int Clin Psychopharmacol. 1987;2(4):333–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Ware JC, Brown FW, Moorad J, Pittard JT, Murphy M, Franklin D. Nocturnal myoclonus and tricyclic antidepressants. Sleep Res. 1984;13:72.Google Scholar
  49. 49.
    Ketl P, DePaulo JR Jr. Maprotiline-induced myoclonus. J Clin Psychopharmacol. 1983;3(4):264–5.CrossRefGoogle Scholar
  50. 50.
    Cording-Tömmel C, von Zerssen D. Mianserin and maprotiline as compared to amitriptyline in severe endogenous depression. A new methodological approach to the clinical evaluation of the efficacy of antidepressants. Pharmacopsychiatria. 1982;15(6):197–204.Google Scholar
  51. 51.
    Paik IH, Lee C, Choi BM, Chae YL, Kim CE. Mianserin-induced restless legs syndrome. Br J Psychiatry. 1989;155:415–7.PubMedGoogle Scholar
  52. 52.
    Markkula J, Lauerma H. Mianserin and restless legs. Int Clin Psychopharmacol. 1997;12(1):53–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Ağargün MY, Kara H, Ozbek H, Tombul T, Ozer OA. Restless legs syndrome induced by mirtazapine. J Clin Psychiatry. 2002;63(12):1179.PubMedCrossRefGoogle Scholar
  54. 54.
    Bahk WM, Pae CU, Chae JH, Jun TY, Kim KS. Mirtazapine may have the propensity for developing a restless legs syndrome? A case report. Psychiatry Clin Neurosci. 2002;56(2):209–10.PubMedCrossRefGoogle Scholar
  55. 55.
    Bonin B, Vandel P, Kantelip JP. Mirtazapine and restless leg syndrome: a case report. Therapie. 2000;55(5):655–6.Google Scholar
  56. 56.
    Markkula J, Lauerma H. Mirtazapine-induced restless legs. Hum Psychopharm. 1997;12(5):497–9.CrossRefGoogle Scholar
  57. 57.
    Park YM, Lee HJ, Kang SG, Cho JH, Kim L. Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder. Psychiatry Investig. 2009;6(4):313–5.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Chopra A, Pendergrass DS, Bostwick JM. Mirtazapine-induced worsening of restless legs syndrome (RLS) and ropinirole-induced psychosis: challenges in management of depression in RLS. Psychosomatics. 2011;52(1):92–4.PubMedCrossRefGoogle Scholar
  59. 59.
    Teive HA, de Quadros A, Barros FC, Werneck LC. Worsening of autosomal dominant restless legs syndrome after use of mirtazapine: case report. Arq Neuropsiquiatr. 2002;60(4):1025–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Fulda S, Kloiber S, Dose T, Lucae S, Holsboer F, Schaaf L, Hennings J. Mirtazapine provokes periodic leg movements during sleep in young healthy men. Sleep. 2013;36(5):661–9.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Askenasy JJ, Yahr MD. Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated? J Neural Transm. 1988;72(1):67–76.PubMedCrossRefGoogle Scholar
  62. 62.
    Levy AB, Bucher P, Votolato N. Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine-tryptophan combination treatment. Can J Psychiatry. 1985;30(6):434–6.PubMedCrossRefGoogle Scholar
  63. 63.
    White PD. Myoclonus and episodic delirium associated with phenelzine: a case report. J Clin Psychiatry. 1987;48(8):340–1.PubMedGoogle Scholar
  64. 64.
    Morgan JL, Brown TM, Wallace ER 4th. Monoamine oxidase inhibitors and sleep movements. Am J Psychiatry. 1994;151(5):782.PubMedGoogle Scholar
  65. 65.
    Grewal M, Hawa R, Shapiro C. Treatment of periodic limb movements in sleep with selegeline HCl. Mov Disord. 2002;17(2):398–401.PubMedCrossRefGoogle Scholar
  66. 66.
    Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med. 1994;12(6):642–4.PubMedCrossRefGoogle Scholar
  67. 67.
    Dimmitt SB, Riley GJ. Selective serotonin receptor uptake inhibitors can reduce restless legs symptoms. Arch Intern Med. 2000;160(5):712.PubMedCrossRefGoogle Scholar
  68. 68.
    Bakshi R. Fluoxetine and restless legs syndrome. J Neurol Sci. 1996;142(1–2):151–2.PubMedCrossRefGoogle Scholar
  69. 69.
    Dorsey CM, Lukas SE, Cunningham SL. Fluoxetine-induced sleep disturbance in depressed patients. Neuropsychopharmacology. 1996;14(6):437–42.PubMedCrossRefGoogle Scholar
  70. 70.
    Lauterbach EC. Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick’s disease. Mov Disord. 1994;9(3):343–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Darko W, Guharoy R, Rose F, Lehman D, Pappas V. Myoclonus secondary to the concurrent use of trazodone and fluoxetine. Vet Hum Toxicol. 2001;43(4):214–5.PubMedGoogle Scholar
  72. 72.
    Sanz-Fuentenebro FJ, Huidobro A, Tejadas-Rivas A. Restless legs syndrome and paroxetine. Acta Psychiatr Scand. 1996;94(6):482–4.PubMedCrossRefGoogle Scholar
  73. 73.
    Oztürk O, Eraslan D, Kumral E. Oxcarbazepine treatment for paroxetine-induced restless leg syndrome. Gen Hosp Psychiatry. 2006;28(3):264–5.Google Scholar
  74. 74.
    Bušková J, Vorlová T, Piško J, Sonka K. Severe sleep-related movement disorder induced by sertraline. Sleep Med. 2012;13(6):769–70.PubMedCrossRefGoogle Scholar
  75. 75.
    Zhang B, Hao Y, Jia F, Li X, Ren Y, Zhou P, Liu W, Wing YK. Sertraline and periodic limb movments during sleep: an 8-week open-label study in depressed patients with insomnia. Sleep Med. 2013;14(12):1405–12.PubMedCrossRefGoogle Scholar
  76. 76.
    Hargrave R, Beckley DJ. Restless leg syndrome exacerbated by sertraline. Psychosomatics. 1998;39(2):177–8.Google Scholar
  77. 77.
    Ghaziuddin N, Iqbal A, Khetarpal S. Myoclonus during prolonged treatment with sertraline in an adolescent patient. J Child Adolesc Psychopharmacol. 2001;11(2):199–202.Google Scholar
  78. 78.
    Perroud N, Lazignac C, Baleydier B, Cicotti A, Maris S, Damsa C. Restless legs syndrome induced by citalopram: a psychiatric emergency? Gen Hosp Psychiatry. 2007;29(1):72–4.Google Scholar
  79. 79.
    Page RL 2nd, Ruscin JM, Bainbridge JL, Brieke AA. Restless legs syndrome induced by escitalopram: case report and review of the literature. Pharmacotherapy. 2008;28(2):271–80.PubMedCrossRefGoogle Scholar
  80. 80.
    Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep. Biol Psychiatry. 2005;58(6):510–4 (Epub 2005 Jul 7).PubMedCrossRefGoogle Scholar
  81. 81.
    Salín-Pascual RJ, Galicia-Polo L, Drucker-Colín R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry. 1997;58(8):348–50.PubMedCrossRefGoogle Scholar
  82. 82.
    Milanlioglu A. Venlafaxine-induced restless legs syndrome. J Psychiatry Neurol Sci. 2012;25(4):388–9.Google Scholar
  83. 83.
    Terao T, Terao M, Yoshimura R, Abe K. Restless legs syndrome induced by lithium. Biol Psychiatry. 1991;30(11):1167–70.PubMedCrossRefGoogle Scholar
  84. 84.
    Heiman EM, Christie E. Lithium-aggravated nocturnal myoclonus and restless legs syndrome. AJ Psychiatry. 1986;143(9):1191–2.Google Scholar
  85. 85.
    Caviness JN, Evidente VG. Cortical myoclonus during lithium exposure. Arch Neurol. 2003;60(3):401–4.PubMedCrossRefGoogle Scholar
  86. 86.
    Bayard M, Bailey B, Acharya D, Ambreen F, Duggal S, Kaur T, Rahman ZU, Roller K, Tudiver F. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2011;24(4):422–8.Google Scholar
  87. 87.
    Kim SW, Shin IS, Kim JM, Yang SJ, Shin HY, Yoon JS. Bupropion may improve restless legs syndrome: a report of three cases. Clin Neuropharmacol. 2005;28(6):298–301.Google Scholar
  88. 88.
    Lee JJ, Erdos J, Wilkosz MF, LaPlante R, Wagoner B. Bupropion as a possible treatment option for restless legs syndrome. Ann Pharmacother. 2009;43(2):370–4.PubMedCrossRefGoogle Scholar
  89. 89.
    Nofzinger EA, Fasiczka A, Berman S, Thase ME. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry. 2000;61(11):858–62.PubMedCrossRefGoogle Scholar
  90. 90.
    Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, Gruber G, Mandl M, Strobl R, Gollner D, Prause W, Saletu B. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(2):249–60.PubMedCrossRefGoogle Scholar
  91. 91.
    Chiodo LA. Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology. Neurosci Biobehav Rev. 1988;12(1):49–91.Google Scholar
  92. 92.
    Kang SG, Lee HJ, Jung SW, Cho SN, Han C, Kim YK, Kim SH, Lee MS, Joe SH, Jung IK, Kim L. Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(5):1078–83.PubMedCrossRefGoogle Scholar
  93. 93.
    Kang SG, Lee HJ, Park YM, Yang HJ, Song HM, Lee YJ, Cho SJ, Cho SN, Kim L. The BTBD9 gene may be associated with antipsychotic-induced restless legs syndrome in schizophrenia. Hum Psychopharmacol. 2013;28(2):117–23.PubMedCrossRefGoogle Scholar
  94. 94.
    Kim SW, Shin IS, Kim JM, Park KH, Youn T, Yoon JS. Factors potentiating the risk of mirtazapine associated restless legs syndrome. Hum Psychpharmacol. 2008;7:615–20.CrossRefGoogle Scholar
  95. 95.
    Nishimatsu O, Horiguchi J, Inami Y, Innami T, Sasaki A, Kondo K. Nocturnal myoclonus observed in a patient with neuroleptic-induced akathisia. Jpn J Psychiatry Neurol. 1992;46(1):121–6.PubMedGoogle Scholar
  96. 96.
    Nishimatsu O, Horiguchi J, Inami Y, Sukegawa T, Sasaki A. Periodic limb movement disorder in neuroleptic-induced akathisia. Kobe J Med Sci. 1997;43(5):169–77.PubMedGoogle Scholar
  97. 97.
    Staedt J, Dewes D, Danos P, Stoppe G. Can chronic neuroleptic treatment promote sleep disturbances in elderly schizophrenic patients? Int J Geriatr Psychiatry. 2000;15(2):170–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Walters AS, Hening W, Rubinstein M, Chokroverty S. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep. 1991;14(4):339–45.PubMedGoogle Scholar
  99. 99.
    Lipinski JF, Hudson JI, Cunningham SL, Aizley HG, Keck PE Jr, Mallya G, Aranow RB, Lukas SE. Polysomnographic characteristics of neuroleptic-induced akathisia. Clin Neuropharmacol. 1991;14(5):413–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Cotter PE. O’Keeffe ST Improvement in neuroleptic-induced akathisia with intravenous iron treatment in a patient with iron deficiency. J Neurol Neurosurg Psychiatry. 2007;78(5):548.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Yamashita H, Horiguchi J, Mizuno S, Kuramoto Y, Yamawaki S, Inami Y. A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep. Psychiatry Clin Neurosci. 1999;53(2):291–3.PubMedCrossRefGoogle Scholar
  102. 102.
    Young WB, Piovesan EJ, Biglan KM. Restless legs syndrome and drug-induced akathisia in headache patients. CNS Spectr. 2003;8(6):450–6.PubMedCrossRefGoogle Scholar
  103. 103.
    Murray TJ. The restless leg syndrome. Can Med Assoc J. 1967;96(24):1571–4.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Bet PM, Franken LG, Klumpers UM. Could pramipexole induce acute mania? A case report. Bipolar Disord. 2013. doi: 10.1111/bdi.12067 (Epub ahead of print).
  105. 105.
    Horiguchi J, Yamashita H, Mizuno S, Kuramoto Y, Kagaya A, Yamawaki S, Inami Y. Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int Clin Psychopharmacol. 1999;14(1):33–6.PubMedGoogle Scholar
  106. 106.
    Shin YK, Hong SC, Ihn YK, Jeong JH, Han JH, Lee SP. A case of a patient with both chorea and restless legs syndrome. J Korean Med Sci. 2008;23(3):533–6.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS. Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial. Neurology. 2003;60(2):315–21.PubMedCrossRefGoogle Scholar
  108. 108.
    Larner AJ. Migraine with aura and restless legs syndrome. J Headache Pain. 2007;2:141–2.CrossRefGoogle Scholar
  109. 109.
    Ehrenberg B. Acute migraine treatment with droperidol: letter to the editor. Neurology. 2003;61:1826.Google Scholar
  110. 110.
    Sandyk R. The restless legs syndrome (Ekbom’s syndrome). BMJ 1983;283:885.Google Scholar
  111. 111.
    Morgan LK. Restless limbs: a commonly overlooked symptom controlled by “valium”. Med J Aust. 1967;2(13):589–94.PubMedGoogle Scholar
  112. 112.
    Jagota P, Asawavichienjinda T, Bhidayasiri R. Prevalence of neuroleptic-induced restless legs syndrome in patients taking neuroleptic drugs. J Neurol Sci. 2012;314(1–2):158–60.PubMedCrossRefGoogle Scholar
  113. 113.
    Duggal H, Mendhekar D. Clozapine-associated restless legs syndrome. Lett J Clin Psychopharm. 2007;27(1):89–90.CrossRefGoogle Scholar
  114. 114.
    Basu A, Kundu S, Khurana H. Olanzapine-induced restless leg syndrome: a case report and review of literature. Indian J Pharmacol. 2014;46(4):450–2.Google Scholar
  115. 115.
    Zhao M, Geng T, Qiao L, Zhang M, Shi J, Huang F, Lin X, Wang J, Zuo H. Olanzapine-induced restless legs syndrome. J Clin Neurosci. 2014;21(9):1622–5.Google Scholar
  116. 116.
    Aggarwal S, Dodd S, Berk M. Restless leg syndrome associated with olanzapine: a case series. Curr Drug Saf. 2010;5(2):129–31.PubMedCrossRefGoogle Scholar
  117. 117.
    Kang SG, Lee HJ, Kim L. Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine. J Psychopharmacol. 2009;23(5):597–601.PubMedCrossRefGoogle Scholar
  118. 118.
    Khalid I, Rana L, Khalid TJ, Roehrs T. Refractory restless legs syndrome likely caused by olanzapine. J Clin Sleep Med. 2009;5(1):68–9.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Kraus T, Schuld A, Pollmächer T. Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol. 1999;19(5):478–9.PubMedCrossRefGoogle Scholar
  120. 120.
    Wetter TC, Brunner J, Bronisch T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry. 2002;35(3):109–11.PubMedCrossRefGoogle Scholar
  121. 121.
    Virit O, Selek S, Savas HA, Kokaçya H. Improvement of restless legs syndrome and trichotillomania with aripiprazole. J Clin Pharm Ther. 2009;34(6):723–5.PubMedCrossRefGoogle Scholar
  122. 122.
    McCall WV, Riley MA, Hodges C, et al. Asenapine-induced restless legs syndrome: differentiation from akathisia. J Clin Sleep Med. 2014;10(12):1341–2.PubMedPubMedCentralGoogle Scholar
  123. 123.
    Rittmannsberger H, Werl R. Restless legs syndrome induced by quetiapine: report of seven cases and review of the literature. Int J Neuropsychopharmacol. 2013;16(6):1427–31.PubMedCrossRefGoogle Scholar
  124. 124.
    Pinninti NR, Mago R, Townsend J, Doghramji K. Periodic restless legs syndrome associated with quetiapine use: a case report. J Clin Psychopharmacol. 2005;25(6):617–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Urbano MR, Ware JC. Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder. J Clin Psychopharmacol. 2008;28(6):704–5.PubMedCrossRefGoogle Scholar
  126. 126.
    Chou KJ, Chen PY, Huang MC. Restless legs syndrome following the combined use of quetiapine and paroxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2010;4:444–5.Google Scholar
  127. 127.
    Tan EK, Ho SC, Koh L, Pavanni R. An urge to move with l-thyroxine: clinical, biochemical, and polysomnographic correlation. Mov Disord. 2004;19(11):1365–7.PubMedCrossRefGoogle Scholar
  128. 128.
    Dzaja A, Wehrle R, Lancel M, Pollmächer T. Elevated estradiol plasma levels in women with restless legs during pregnancy. Sleep. 2009;32(2):169–74.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Wesstrom J, Nilsson S, Sundstrom-Poromaa I, Ulfberg J. Restless legs syndrome among women: prevalence, co-morbidity and possible relationship to menopause. Climacteric. 2008;11(5):422–8.PubMedCrossRefGoogle Scholar
  130. 130.
    Sieminski M, Karwacka M, Nyka W. Restless legs syndrome and hormonal replacement therapy in women at menopausal age. Neurology. 2012. Meeting Abstracts P05.010.Google Scholar
  131. 131.
    Jeret JS. Diltiazem–induced myoclonus. Neurology. 2002;59(6):962.Google Scholar
  132. 132.
    Swanoski MT, Chen JS, Monson MH. Myoclonus associated with long-term use of diltiazem. Am J Health Syst Pharm. 2011;68(18):1707–10.PubMedCrossRefGoogle Scholar
  133. 133.
    Gonzalez L, Feijoo M. Myoclonus and angiotensin converting enzyme inhibitors. Med Clin (Barc). 2005;125(10):398.Google Scholar
  134. 134.
    Morgan LK. Restless legs: precipitated by beta-blockers, relieved by orphenadrine. Letter. Med J Aust. 1975;2(19):753.PubMedGoogle Scholar
  135. 135.
    Strang RR. The symptom of restless legs. Med J Aust. 1967;1(24):1211–3.PubMedGoogle Scholar
  136. 136.
    Ginsberg HN. Propranolol in the treatment of restless legs syndrome induced by imipramine withdrawal. Am J Psychiatry. 1986;143(7):938.PubMedGoogle Scholar
  137. 137.
    O’Sullivan RL, Greenberg DB. H2 antagonists, restless leg syndrome, and movement disorders. Psychosomatics. 1993;34(6):530–2.Google Scholar
  138. 138.
    Hogue R, Chesson AL. Pharmacologically induced/exacerbated restless legs syndrome, peirodic limb movements of sleep, and REM behavior disorder/REM without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med. 2010;6(1):79–83.Google Scholar
  139. 139.
    Pichietti D, Winkelman JW. Restless legs syndrome, periodic limb movements in sleep and depression. Sleep. 2005;28(7):891–8.Google Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Department of MedicineTulane University School of MedicineNew OrleansUSA
  2. 2.Advanced Sleep CenterMetairieUSA

Personalised recommendations